Krishna Institute of Medical Sciences Limited will convene its 24th Annual General Meeting (AGM) on Thursday, August 27, 2026, at 4:00 PM IST via Video Conferencing/Other Audio Visual Means (VC/OAVM). The meeting aims to adopt the audited financial statements for FY26, re-appoint a retiring director, and seek shareholder approval for significant financial powers, including loan and guarantee limits up to ₹650 crore. This approval is critical for the company’s ongoing capital expenditure and working capital requirements within the KIMS group.

The notice, issued pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was published in Financial Express and Navatelangana on August 6, 2026. The filing outlines both ordinary and special business items, ensuring compliance with corporate governance norms while facilitating remote participation for shareholders.

Key Resolutions for Approval

The AGM agenda features three critical resolutions requiring shareholder consent:

Under Item 3, the Board seeks to ratify the remuneration of ₹6.00 Lakhs, excluding applicable taxes, payable to M/s. Sagar & Associates for conducting the cost audit for FY27. This appointment was recommended by the Audit Committee.

Financial Powers and Compliance

Items 4 and 5 involve special resolutions to expand the company’s financial flexibility. Under Section 185 of the Companies Act, 2013, the Board seeks approval to provide loans, guarantees, or securities to subsidiaries, associates, or joint ventures where directors have an interest, up to ₹650 crore over and above Section 186 limits. Similarly, under Section 186, the Board seeks approval for loans, guarantees, or investments in other bodies corporate up to ₹650 crore over the statutory limit of 60% of paid-up capital, free reserves, and securities premium, or 100% of free reserves and securities premium, whichever is higher.

The explanatory statement clarifies that these funds are intended for principal business activities, working capital requirements, and capital expenditure for new projects within the KIMS group. The Audit Committee will monitor these transactions periodically to ensure compliance with arm’s length principles and regulatory requirements. No directors or key managerial personnel have a financial interest in these resolutions.

Voting and Participation Details

Shareholders holding shares as of the record date, August 20, 2026, are eligible to vote. Remote e-voting will be available from August 24, 2026, at 9:00 AM IST to August 26, 2026, at 5:00 PM IST, facilitated by MUFG Intime India Private Limited. Members who vote remotely may still attend the AGM via VC/OAVM but cannot vote again during the meeting. Physical attendance is dispensed with as per Ministry of Corporate Affairs circulars.

Krishna Institute of Medical Sciences Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the stock exchanges on August 5, 2026, in compliance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report is accompanied by an Independent Practitioner's Reasonable Assurance Report issued by M/s. Brahmayya & Co., Chartered Accountants, and forms part of the company's 24th Integrated Annual Report. The BRSR presents the company's performance against the nine principles of the National Guidelines on Responsible Business Conduct (NGRBC) and SEBI's BRSR framework, covering environmental stewardship, social responsibility, and governance.

Business Overview and Operations

Krishna Institute of Medical Sciences operates in the hospital and medical care segment, which accounts for 96.78% of its turnover. The company offers comprehensive healthcare services across 40 specialties, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopedics, organ transplantation, renal sciences, and mother & child care. As of the reporting period, the company operates 6 hospitals nationally across 3 states, with no international operations. Exports contributed 1.67% to total turnover. The company reported a turnover of ₹17,013.77 Million and a net worth of ₹24,283.69 Million, making it subject to CSR obligations under Section 135 of the Companies Act, 2013.

The company's subsidiary and associate structure as disclosed in the BRSR is summarised below:

Environmental Performance

The BRSR discloses detailed environmental metrics for FY 2025-26, independently assured by M/s. Brahmayya & Co. Key energy, water, and emissions data are presented below:

Air emission parameters disclosed for FY 2025-26 include NOx at 28.66 µg/m³, SOx at 25.97 µg/m³, and Particulate Matter (PM) at 41.78 µg/m³. The company has implemented a Zero Liquid Discharge (ZLD) system, with treated sewage reused for toilet flushing, cooling systems, and landscaping across multiple facilities. Scope 3 emissions were not measured during the reporting year, with the company noting that efforts are ongoing to track and record this data.

Workforce and Social Disclosures

The BRSR provides detailed workforce data, including employee well-being, safety, and human rights metrics. The cost incurred on wellbeing measures as a percentage of total revenue was 0.13% in FY 2025-26, compared to 0.16% in FY 2024-25. No lost-time injuries, fatalities, or high-consequence work-related injuries were recorded for either employees or workers in FY 2025-26 or FY 2024-25.

Board gender diversity stood at 22.2% female representation (2 out of 9 directors), while 50% of Key Managerial Personnel are female (1 out of 2). No disciplinary actions for bribery or corruption were recorded against any directors, KMPs, employees, or workers in FY 2025-26 or FY 2024-25.

Governance and Transparency

The company reported accounts payable days of 124.40 in FY 2025-26, compared to 125.29 in FY 2024-25. Purchases from trading houses as a percentage of total purchases rose to 74.23% in FY 2025-26 from 67% in FY 2024-25, with the number of trading houses increasing from 890 to 1,465. Purchases from the top 10 trading houses as a percentage of total trading house purchases stood at 30.83%, up from 24.00%.

No penalties, fines, or compounding fees were paid to any regulatory, law enforcement, or judicial authority during FY 2025-26. No complaints related to conflict of interest involving directors or KMPs were received in either the current or previous reporting year.

CSR and Community Initiatives

The company undertook a range of CSR projects at the group level during the reporting period, benefiting diverse stakeholder groups across education, healthcare, and skill development. Notable initiatives included health camps reaching 81,258 beneficiaries, cancer screening camps covering 16,500 individuals, and skill development programmes through partnerships such as KFRC-Tech Mahindra Foundation in Secunderabad (319 beneficiaries) and Vizag (205 beneficiaries). Job creation was concentrated in metropolitan areas, accounting for 76.68% of total wage cost in FY 2025-26, compared to 71.37% in FY 2024-25. Sourcing from within the district and neighbouring districts stood at 91.18% in FY 2025-26, marginally lower than 91.81% in FY 2024-25.

The BRSR, along with the Independent Practitioner's Reasonable Assurance Report, is available on the company's website at https://www.kimshospitals.com/investors/ under Regulation 46 of SEBI (LODR) Regulations, 2015.